Emergent Biosolutions

This study will check how safe and effective the CYFENDUS anthrax vaccine is when given to people after a large anthrax exposure. Researchers will look at medical records of about 250 people who received the vaccine during a real mass exposure event in the United States. The goal…

This study will test a drug called AIGIV in people who have inhaled anthrax during a large-scale exposure event. Researchers will track how many patients survive and how the drug affects the body. The goal is to see if AIGIV is safe and helps people recover from this serious infe…

This study looks at how safe and helpful AIGIV is for people with a serious form of anthrax infection. Researchers will track survival, side effects, and drug levels in up to 10 patients. The goal is to gather real-world information on how well the treatment works.

This study will look at how well the drug raxibacumab works and how safe it is for people who get sick with inhalational anthrax after a large-scale exposure, like a bioterrorist attack. About 100 people of all ages, including pregnant women, who receive the drug from the nationa…

This study will observe up to 10 people in the US who have lab-confirmed anthrax and are treated with the drug raxibacumab. Researchers want to see how well the drug works, including survival rates and side effects, by collecting data from medical records and blood samples. The g…